Recce Pharmaceuticals Ltd. announced the Board of Directors has unanimously appointed Michele Dilizia to the role of Chief Scientific Officer. Ms Dilizia will also continue her role as Executive Director and as member of the Board of Directors. Ms Dilizia's specilisation is in medical microbiology and regulatory affairs. Michele successfully co-led the research and development of Recce's suite of anti-infective compounds, resulting in a portfolio of granted patents across the globe, including a Qualified Infectious Disease Product designation with the FDA. Ms. Dilizia will deliver the Opening R&D Address at the World Anti-Microbial Resistant (AMR) Congress in the coming week, where she will present Synthetic Antibiotics: The New Approach the World Needs to be centred around Recces leading anti-infective pipeline in the space.